BiotechTube

P03277

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Central Nervous System Indication

Conditions

Central Nervous System Indication, Pediatric Patients, Body Indication

Trial Timeline

Nov 6, 2018 → Aug 10, 2020

NCT ID
NCT03749252

About P03277

P03277 is a phase 2 stage product being developed by Guerbet for Central Nervous System Indication. The current trial status is completed. This product is registered under clinical trial identifier NCT03749252. Target conditions include Central Nervous System Indication, Pediatric Patients, Body Indication.

What happened to similar drugs?

4 of 20 similar drugs in Central Nervous System Indication were approved

Approved (4) Terminated (2) Active (14)
🔄Placebo + MirogabalinDaiichi SankyoPhase 3
✅amphotericin B liposomal (Ambisome)Astellas PharmaApproved
🔄Tirabrutinib + Rituximab + TemozolomideOno PharmaceuticalPhase 3
🔄Leuprolide Acetate (LA)AbbViePhase 3
🔄temozolomideMerckPhase 3
🔄ranibizumab + ranibizumabNovartisPhase 3
🔄Ranibizumab 0.5 mgNovartisPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT03749252Phase 2Completed
NCT03657784Phase 1Completed

Competing Products

20 competing products in Central Nervous System Indication

See all competitors
ProductCompanyStageHype Score
Placebo + MirogabalinDaiichi SankyoPhase 3
40
filgrastim + exatecan mesylateDaiichi SankyoPhase 1
29
amphotericin B liposomal (Ambisome)Astellas PharmaApproved
43
Methotrexate + Ibrutinib + TemozolomideSun PharmaceuticalPhase 2
31
alcohol + placebo + alcohol + perampanel + perampanel + alcohol + placebo + alcoholEisaiPhase 1
29
perampanelEisaiPhase 2
35
Tirabrutinib + PlaceboOno PharmaceuticalPhase 2
42
TirabrutinibOno PharmaceuticalPhase 1
36
ONO-4059 + Rituximab + Methotrexate + Procarbazine + VincristineOno PharmaceuticalPhase 1
33
Tirabrutinib + Rituximab + TemozolomideOno PharmaceuticalPhase 3
47
Tirabrutinib + Tirabrutinib + TirabrutinibOno PharmaceuticalPhase 2
39
pemetrexedEli LillyPhase 1
29
HRS-9231 + GadobutrolJiangsu Hengrui MedicinePhase 2
42
Leuprolide Acetate (LA)AbbViePhase 3
40
AcalabrutinibAstraZenecaPhase 2
39
Durvalumab + AcalabrutinibAstraZenecaPhase 1
33
Avelumab + LenvatinibMerckPhase 1
33
temozolomideMerckPhase 3
44
Ibrutinib + Pembrolizumab + RituximabMerckPhase 1/2
39
TemozolomideMerckPhase 2
35